公开(公告)号：EP1246612B1

公开(公告)日：2008-06-11

申请号：EP01900942.2

申请日：2001-01-08

申请人： Osmotica Corp.

发明人： FAOUR, Joaquina ,  RICCI, Marcelo, A.

IPC分类号： A61K9/22 ,  A61K9/24 ,  A61K9/44 ,  A61K31/137 ,  A61K31/445

CPC分类号： A61K31/505 ,  A61K9/0004 ,  A61K9/209 ,  A61K31/40 ,  A61K31/415 ,  A61K31/445 ,  A61K31/495 ,  A61K31/54 ,  A61K31/55 ,  A61K31/135 ,  A61K2300/00

摘要： The present invention provides an osmotic device containing controlled release pseudoephedrine in the core in combination with a rapid release H1 antagonist in an external coat. A wide range of H1 antagonist antihistamines, especially fexofenadine, can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray coated rather than compression coated onto the device. The device with spray coated external core is smaller and easier to swallow than the similar device having a compression coated external coat. The device is useful for the treatment of respiratory congestion related disorders and allergy related disorders. The present devices provide PS and an H1 antagonist according to specific release profiles in combination with specific formulations.

公开(公告)号：EP1246613A1

公开(公告)日：2002-10-09

申请号：EP01901848.0

申请日：2001-01-08

申请人： Osmotica Corp.

发明人： FAOUR, Joaquina ,  COPPARI, Marcelo, A.

IPC分类号： A61K9/22

CPC分类号： A61K9/0004

摘要： The delivery devices (20) described herein are capable of delivering one or more active substances by osmotic pumping through preformed passageways (26, 27). An osmotic device according to the invention includes a first osmotic device enclosed within a second osmotic device. The first osmotic device includes drug-containing core (25) surrounded by a first semipermeable membrane (24). The second osmotic device includes a drug-containing composition (23) surrounding the first semipermeable membrane and a second semipermeable membrane (22) surrounding the drug-containing composition. The device can also include an external drug-containing composition (21). In some embodiments, the semipermeable membrane of one or both of the osmotic devices completely dissolves or degrades during use. This delivery device can include an immediate release outer coat.

公开(公告)号：EP1248598A1

公开(公告)日：2002-10-16

申请号：EP01901878.7

申请日：2001-01-08

申请人： Osmotica Corp.

发明人： FAOUR, Joaquina

IPC分类号： A61K9/22

CPC分类号： A61K9/0004

摘要： The present invention provides a simple and improved osmotic device (1) that is capable of providing a controlled release of active agent contained in the core (4) through a preformed passageway (5) into an environment of use. The preformed passageway (5) increases in size during use of the osmotic device (1) thereby increasing the release rate of the active agent, enabling the release of large particles containing active agent, and enabling the release of active agents that are substantially insoluble in the environment of use.

公开(公告)号：EP1714641B8

公开(公告)日：2010-05-19

申请号：EP05850136.2

申请日：2005-01-03

申请人： Osmotica Corp.

发明人： FELEDER, Ethel C. ,  MEYER, Glenn A. ,  RICCI, Marcelo A. ,  BEFUMO, Marcelo F. ,  FAOUR, Joaquina ,  PASTINI, Ana C.

IPC分类号： A61K9/32 ,  A61K31/137

CPC分类号： A61K9/0004 ,  A61K31/13 ,  A61K31/137 ,  A61K31/277

公开(公告)号：EP2070518A2

公开(公告)日：2009-06-17

申请号：EP07817380.4

申请日：2007-07-24

申请人： Osmotica Corp.

发明人： FAOUR, Joaquina ,  PASTINI, Ana C.

IPC分类号： A61K9/00 ,  A61K47/32 ,  A61K47/36

CPC分类号： A61K9/0048 ,  A61K9/08

摘要： Aqueous ophthalmic solutions containing a combination of hyaluronic acid or a pharmaceutically acceptable salt thereof, e.g. sodium hyaluronate, and polyvinyl alcohol are disclosed. These solutions have a synergistic effect on viscosity and provide a statistically significant improvement over the prior art formulations. The solutions are used as artificial tear for the treatment of dry eye syndrome and ocular discomfort and may be administered whenever the use of artificial tears is advisable. The solutions are also suitable for use as vehicle for ophthalmic drugs.

摘要翻译： 含有透明质酸或其药学上可接受的盐的组合的水性眼用溶液，例如， 透明质酸钠和聚乙烯醇。 这些溶液对粘度具有协同效应，并提供比现有技术制剂统计学显着的改进。 该溶液被用作治疗干眼综合征和眼部不适的人造泪液，并且可以在使用人造泪液时施用。 该溶液也适合用作眼科药物的载体。

公开(公告)号：EP1600156A2

公开(公告)日：2005-11-30

申请号：EP04738449.0

申请日：2004-03-05

申请人： Osmotica Corp.

发明人： VERGEZ, Juan, A. ,  LANIER, Alan, B. ,  FELEDER, Ethel, C. ,  MEYER, Glenn, A. ,  RICCI, Marcelo, A. ,  FAOUR, Joaquina

IPC分类号： A61K31/13

CPC分类号： A61K45/06 ,  A61K31/00 ,  A61K31/137 ,  A61K31/343 ,  A61K31/452 ,  A61K2300/00

摘要： The invention provides a method, and dosage form therefor, of treating impaired motor function associated with Parkinson's disease, anti-Parkinson's drug treatment, e.g. L-Dopa therapy, and/or dementia associated with Parkinson's disease. The invention includes the combined administration of an NMDA receptor antagonist and an antidepressant, e.g., the combination of amantadine and citalopram or venlafaxine, or an NMDA receptor antagonist and an anxiolytic agent, e.g., amantadine and buspirone or trazodone, for the amelioration of undesired tremors, akinesia, dyskinesia, or bradykinesia associated with one or more different disorders or diseases.
The drugs can be included in a single dosage form. One embodiment includes a combination dosage form containing each drug in controlled release forms. Another embodiment includes a combination dosage form providing a controlled release of an NMDA receptor antagonist and a rapid release of a neuroactive agent after administration to a subject.

摘要翻译： 本发明提供了一种治疗与帕金森病相关的运动功能受损，抗帕金森氏病药物治疗的方法及其剂型。 左旋多巴治疗和/或与帕金森病相关的痴呆症。 本发明包括联合施用NMDA受体拮抗剂和抗抑郁药，例如金刚烷胺和西酞普兰或文拉法辛或NMDA受体拮抗剂和抗焦虑剂（例如金刚烷胺和丁螺环酮或曲唑酮）的组合，用于改善不期望的颤抖 ，运动障碍，运动障碍或与一种或多种不同疾病或疾病相关的运动迟缓。 药物可以包含在单一剂型中。 一个实施方案包括含有受控释放形式的每种药物的组合剂型。 另一个实施方案包括提供NMDA受体拮抗剂的受控释放的组合剂型和在施用于受试者之后神经活性剂的快速释放。

公开(公告)号：EP1253910A1

公开(公告)日：2002-11-06

申请号：EP01901869.6

申请日：2001-01-08

申请人： Osmotica Corp.

发明人： FAOUR, Joaquina

IPC分类号： A61K9/20 ,  A61K9/22 ,  A61K9/24 ,  A61K9/28 ,  A61K9/30 ,  A61K9/36

CPC分类号： A61K9/0004

摘要： A delivery device [(1) in Figure 1a] capable of delivering one or more active substances by diffusion through plural micropores in the membrane (4) or by osmotic pumping through one or more performed passageways (5) in the membrane is provided. The device (1) contains a centrally located expandable core (2) completely surrounded by an active substance containing layer (3), which is completely surrounded by the membrane (4). The device is capable of delivering insoluble, slightly soluble, sparingly soluble and very soluble active substances to an environment of use. The preferred delivery rate is zero order. The device can deliver an active substance for a period of about 12-24 hours.

公开(公告)号：EP1909768A1

公开(公告)日：2008-04-16

申请号：EP06828467.8

申请日：2006-08-04

申请人： Osmotica Corp.

发明人： BEFUMO, Marcelo ,  RICCI, Marcelo A. ,  FELEDER, Ethel C. ,  MEYER, Glenn A. ,  FAOUR, Joaquina ,  VERGEZ, Juan A.

IPC分类号： A61K9/24 ,  A61K9/32 ,  A61K31/198 ,  A61K9/22

CPC分类号： A61K9/2009 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/2866 ,  A61K31/137 ,  A61K31/198 ,  A61K45/06

摘要： The invention provides a compressed tablet that provides a extended release tablet containing a extended release form of carbidopa and a extended release form of levodopa. The tablet optionally further comprises an immediate or rapid release composition of carbidopa and/or levodopa. The extended release composition in the tablet excludes a release rate-controlling polymer, and a release rate-controlling coating; however, the release of the carbidopa and/or levodopa is independently optionally delayed for a lag time. The invention also provides a tablet having a extended release form of levodopa and a rapid or immediate release form of carbidopa. A tablet can contain levodopa present in extended release form and rapid or immediate release form, and carbidopa present in extended release form and rapid or immediate release form. The tablet is used to treat Parkinson's disease and other movement related disorders, diseases or syndromes.

公开(公告)号：EP1248598B1

公开(公告)日：2006-12-13

申请号：EP01901878.7

申请日：2001-01-08

申请人： Osmotica Corp.

发明人： FAOUR, Joaquina

IPC分类号： A61K9/22 ,  A61K9/00 ,  A61K31/4422

CPC分类号： A61K9/0004

摘要： The present invention provides a simple and improved osmotic device (1) that is capable of providing a controlled release of active agent contained in the core (4) through a preformed passageway (5) into an environment of use. The preformed passageway (5) increases in size during use of the osmotic device (1) thereby increasing the release rate of the active agent, enabling the release of large particles containing active agent, and enabling the release of active agents that are substantially insoluble in the environment of use.

公开(公告)号：EP1629835A2

公开(公告)日：2006-03-01

申请号：EP04738451.6

申请日：2004-05-21

申请人： Osmotica Corp.

发明人： FAOUR, Joaquina ,  VERGEZ, Juan, A.

IPC分类号： A61K9/28

CPC分类号： A61K9/0004 ,  A61K9/209

摘要： The present invention provides a simple and improved osmotic device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use. One or both of the passageways optionally increases in size during use of the osmotic device. The preformed passageway and/or the second passageway increase the release rate of the active agent, enable the release of large particles containing active agent, and/or enable the release of active agents that are substantially insoluble in the environment of use. By virtue of the in situ formation of the second aperture, the device is able to release a greater overall percentage of active agent than it would release in absence of the second aperture.

摘要翻译： 本发明提供了一种简单且改进的渗透装置，其能够首先通过预先形成的通道提供包含在芯中的活性剂的受控释放，然后通过原位形成的第二通道进入使用环境。 在使用渗透装置期间，一个或两个通道的尺寸可选地增加。 预形成的通道和/或第二通道增加了活性剂的释放速率，使得能够释放含有活性剂的大颗粒，和/或使基本上不溶于使用环境的活性剂的释放。 由于第二孔的原位形成，该装置能够释放比不存在第二孔时释放的活性剂的更大的总百分比。